Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Hims & Hers Health’s third quarter results prompted a positive market reaction as the company delivered strong revenue growth driven by surging demand for personalized care, new specialty launches, and expanding international reach. Management credited its vertically integrated compounding infrastructure and the transition to multi-condition daily treatments for fueling scale and efficiency. CEO Andrew Dudum highlighted that “subscribers using personalized solutions grew 50% year-over-year,” underscoring the company’s evolution from serving narrow health needs to supporting a broad array of conditions. The company’s ability to leverage its growing customer base for improved engagement and operational learnings featured prominently in its assessment of the quarter.

The company continues to have a strong growth outlook ahead.

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 6.9% in the morning session after the company reported third-quarter 2025 results that showed strong revenue growth, even as its profit and future guidance fell short of expectations. 

Hims & Hers Health (HIMS) CEO Andrew Dudum, sees potential for emotional and medical transformation and plans for global expansion.

Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 49.2% year on year to $599 million. On the other hand, next quarter’s revenue guidance of $615 million was less impressive, coming in 2.6% below analysts’ estimates. Its GAAP profit of $0.06 per share was 40.5% below analysts’ consensus estimates.

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

PLTR, KMB, HIMS, NVTS, CIFR were among the stocks seen trending among investors on Monday, Nov. 3, 2025.

Hims Hers (HIMS) Q3 2025 Earnings Call Transcript

Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of renewed discussions with Novo Nordisk A/S (NYSE: NVO) regarding the potential distribution of Wegovy. While the telehealth platform reported a

Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock.

Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 49.2% year on year to $599 million. On the other hand, next quarter’s revenue guidance of $615 million was less impressive, coming in 2.6% below analysts’ estimates. Its GAAP profit of $0.06 per share was 43.7% below analysts’ consensus estimates.

Here's a look at the Q3 earnings report from Hims & Hers Health.

U.S. stock futures advanced on Monday after Friday’s positive moves. Futures of major benchmark indices were higher.

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings this Monday afternoon. Here’s what you need to know.

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.4% in the afternoon session after JPMorgan Chase & Co. disclosed in a regulatory filing that it had taken a significant passive stake in the company. 

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".